Overview


Asthma is a chronic respiratory condition indicated by inflammation of the airways, especially the narrow tubes known as bronchi, responsible for carrying air into and out of the lungs. In asthmatic patients, the bronchi will be inflamed and more sensitive than normal, producing extra mucus. This can make breathing difficult due to bronchospasm or reversible airflow obstruction and trigger coughing, wheezing, and shortness of breath. Additionally, anti-asthma drugs are medications used to manage and treat asthma. These medications work by various mechanisms to control and relieve these symptoms. Drugs indicated for asthma treatment include the classes of Bronchodilators, beta2 agonists, antimuscarinics, corticosteroids, leukotriene inhibitors, and Monoclonal antibodies. They are available in the form of inhalations, capsules, tablets, injections, etc., and used depending on medical conditions and supervision.

Bronchodilators are a type of medication that helps relieve symptoms related to asthma, COPD, and other lung conditions by relaxing the muscles in the lungs and widening the airways (bronchi). They are divided into two types, including short-acting bronchodilators and long-acting bronchodilators. Short-acting bronchodilators quickly reduce or stop sudden acute asthma symptoms. They’re effective for about 3-6 hours. It is also referred to as a rescue inhaler. Inhalers are devices containing medicine in a plastic container with a mouthpiece. When an inhaler is sprayed, it gives a consistent dose of medication. Also, long-acting bronchodilators keep the airways open for up to 12 hours. They are used daily to prevent asthma attacks. It is taken as an inhaler, tablet, or nebulizer solution. Side effects may include nausea, dry mouth, hyperactivity, and vomiting.

FutureWise Market Research has published a report that provides an insightful analysis anti-asthma drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti-asthma drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • GlaxoSmithKline
  • Merck and Co
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Teva Pharmaceutical
  • Novartis International
  • Boehringer Ingelheim
  • Sunovion Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Anti-Asthma Drugs Market:

  • In January 2023, AstraZeneca, a research-based biopharmaceutical company, received Food and Drug Administration approval for Airsupra, a first-in-class pressurized metered-dose inhaler (pMDI) containing albuterol and budesonide. The treatment is expected to help in the prevention of bronchoconstriction and decrease the exacerbation risk in asthma patients above 18.

The increasing global prevalence of asthma is a major driver for the anti-asthma drug market. With millions suffering from respiratory conditions, there is a constant and critical need for effective treatments. This demand is spurred by factors including urbanization, environmental pollutants, and changing lifestyles, which contribute to the growing incidence of asthma. Thus, pharmaceutical companies and healthcare professionals are propelled to invest in research and development activities, leading to the continuous innovation of anti-asthma medications to cater to this patient population, further boosting the target market. Moreover, the advancement in personalized medicine and the identification of specific biomarkers is anticipated to drive the growth of the anti-asthma drugs market. As we delve into a deeper understanding of asthma patients' unique genetic and molecular profiles, we may tailor treatments with remarkable precision. The identification of specific biomarkers linked to asthma allows for a subtler approach, targeting the underlying causes rather than employing generic solutions. This enhances treatment effectiveness and reduces the risk of side effects that are generally associated with less targeted therapies. Consequently, asthma care is expected to transform as therapies become increasingly tailored to the individual, leading to enhanced outcomes and an improved quality of life for those affected by chronic respiratory conditions. However, the emergence of biological therapies in asthma treatment will likely restrain the traditional pharmaceutical market. As these biologics offer targeted and personalized approaches customized to specific patient populations, they also present challenges in terms of accessibility and affordability. These innovative treatments are expensive and may not be available or covered by all healthcare services or insurance plans. This could lead to disparity in treatment options, potentially limiting access for specific cohorts who may benefit from these advanced therapies. Therefore, the coexistence of biologics compared to traditional pharmaceuticals raises essential concerns regarding equity and integration in asthma care. Therefore, hindering the target over the forecast period.

By Type

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Corticosteroids
  • Monoclonal antibody

By Application

  • Clinics
  • Hospitals
  • Other

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to factors such as the rise in the geriatric population, susceptibility to acquiring respiratory diseases such as asthma, the rising frequency of disorders like asthma, increased research and development activities, better screening and distribution of healthcare facilities, and the rising adoption of inhaled therapeutics in the United States, has largest revenue share driving the market growth. For instance, according to America’s Health Rankings, in 2021, the U.S. had more than 55.8 million individuals aged above 65, which approximates 16.8% of its population that is prone to asthma. Therefore, the above-mentioned- factors are anticipated to boost the target market during the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti Asthma Drugs Market By Type, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Anti Asthma Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti Asthma Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Anti Asthma Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals and Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Anti Asthma Drugs Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Bronchodilators
        2. Leukotriene antagonists
        3. Mast cell stabilizers
        4. Corticosteroids
        5. Monoclonal antibody

  • 8.   Global Anti Asthma Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinics
        2. Hospitals
        3. Other

  • 9.   North America Anti Asthma Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Anti Asthma Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Anti Asthma Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Anti Asthma Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck and Co
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. F. Hoffmann-La Roche
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis International
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Boehringer Ingelheim
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sunovion Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Anti-Asthma TDM Assay Kits Market

Read More
Partner

Our Clients